Sex-Specific Differences in Cardiovascular Disease: Understanding Gender-Related Risk Factors, Diagnosis, and Treatment

Abstract

Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality worldwide, but a growing body of evidence highlights significant sex-specific differences in cardiovascular risk, presentation, and outcomes. This review synthesizes contemporary research and guideline-based insights into the epidemiology, pathophysiology, clinical features, diagnostic approaches, and management strategies for CVD in men and women. Emphasis is placed on mechanisms underlying sex disparities, including hormonal influences, genetic factors, and sociocultural determinants, as well as practical implications for clinical practice. The review also discusses recent advances in sex-tailored therapies and the importance of integrating sex-specific considerations into cardiovascular risk assessment and management to optimize patient outcomes.

Introduction

Cardiovascular risk is influenced by a complex interplay of biological, environmental, and sociocultural factors, many of which differ substantially between sexes. Traditional approaches to CVD prevention and management have largely been derived from studies conducted predominantly in male populations, potentially overlooking critical sex-specific nuances. Recent years have seen a paradigm shift toward recognizing the unique cardiovascular risk profiles, clinical presentations, and therapeutic responses observed in women and men. This article aims to provide a comprehensive overview of sex-specific differences in cardiovascular risk, integrating evidence from recent epidemiological studies, mechanistic research, and clinical guidelines to inform best practices for healthcare professionals.

Epidemiology / Disease Burden

Globally, CVD is the leading cause of death in both sexes, yet the incidence, prevalence, and mortality rates exhibit marked sex differences. Men generally experience the onset of coronary artery disease (CAD) approximately 7–10 years earlier than women. Women, however, tend to have worse outcomes following myocardial infarction and are more likely to die from heart failure, particularly after menopause. Epidemiological data also reveal that women are underdiagnosed and undertreated for CVD, contributing to higher morbidity and mortality. The increasing prevalence of risk factors such as obesity and diabetes in women, particularly in younger age groups, underscores the need for heightened vigilance and tailored preventive strategies.

Pathophysiology

Sex-specific pathophysiological mechanisms are central to differences in cardiovascular risk and disease manifestation. In women, endogenous estrogen confers vascular protection through mechanisms such as enhanced nitric oxide production, reduced vascular inflammation, and favorable lipid profiles. However, the decline in estrogen post-menopause leads to endothelial dysfunction, increased arterial stiffness, and heightened susceptibility to atherosclerosis. In contrast, men are more prone to plaque rupture and obstructive coronary disease, while women more frequently present with microvascular dysfunction and non-obstructive CAD. Genetic factors, such as sex chromosome-linked gene expression, and differences in myocardial structure and autonomic regulation further modulate cardiovascular risk profiles between sexes.

Risk Factors

Traditional risk factors—hypertension, dyslipidemia, diabetes, smoking, and obesity—are prevalent in both sexes but exhibit differential impact. Diabetes confers a disproportionately higher risk of CVD in women than in men. Similarly, smoking and hypertension are more strongly associated with myocardial infarction in women. Unique female-specific risk factors, such as adverse pregnancy outcomes (pre-eclampsia, gestational diabetes), early menopause, and polycystic ovary syndrome, further elevate long-term cardiovascular risk. Psychosocial factors, including depression and chronic stress, are more prevalent in women and have been linked to adverse cardiovascular outcomes. Recognition of these sex-specific and sex-predominant risk factors is essential for effective risk stratification.

Clinical Features

Sex differences in symptom presentation contribute to diagnostic challenges and disparities in outcomes. Women are more likely to present with atypical or non-chest pain symptoms during acute coronary syndromes, including dyspnea, fatigue, or epigastric discomfort, which may delay recognition and treatment. Men typically exhibit classic exertional angina or crushing chest pain. Women are also at greater risk for conditions such as spontaneous coronary artery dissection and Takotsubo cardiomyopathy, often triggered by emotional stress. These differences necessitate a high index of suspicion and tailored diagnostic pathways in clinical practice.

Diagnosis

Diagnostic algorithms must account for sex-specific variations in disease presentation and pathophysiology. Non-invasive testing modalities, such as exercise treadmill testing, have lower sensitivity and specificity in women due to baseline ECG abnormalities and lower pre-test probability. Advanced imaging techniques, including coronary CT angiography and cardiac MRI, offer improved diagnostic yield for non-obstructive and microvascular disease, particularly in women. Biomarker interpretation should also be sex-specific, as established reference ranges for troponin and natriuretic peptides may differ between sexes. A personalized approach to diagnostic evaluation is crucial for accurate risk assessment.

Treatment & Management

Evidence-based pharmacologic therapies antiplatelets, statins, beta-blockers, ACE inhibitors are effective in both sexes but are often underutilized in women. Women are less likely to receive guideline-directed medical therapy or timely reperfusion during acute coronary syndromes, contributing to poorer outcomes. Sex-based differences in drug pharmacokinetics and pharmacodynamics may influence efficacy and adverse event profiles, necessitating careful dosing and monitoring. Non-pharmacologic interventions, including cardiac rehabilitation and lifestyle modification, are equally beneficial in both sexes, yet referral rates for women remain suboptimal. Addressing these disparities requires clinician awareness and systems-level interventions.

Recent Advances / Emerging Therapies

Recent advances highlight the importance of sex-specific research in cardiovascular medicine. Trials evaluating novel lipid-lowering agents, such as PCSK9 inhibitors, have demonstrated comparable efficacy in both sexes, but further studies are needed for women, who are often underrepresented in clinical trials. Hormone replacement therapy remains controversial; current evidence does not support its use for primary or secondary CVD prevention. Novel approaches targeting microvascular dysfunction and inflammation are promising, particularly for women with non-obstructive CAD. Ongoing research into genetic and molecular markers may enable more precise, individualized risk stratification and therapeutic interventions by sex.

Guideline Recommendations

Contemporary guidelines from the American Heart Association and European Society of Cardiology emphasize the importance of sex-specific cardiovascular risk assessment, particularly in women with pregnancy-related complications or early menopause. Risk calculators should incorporate female-specific factors for accurate estimation. Guidelines advocate for equitable application of evidence-based therapies, increased awareness of atypical presentations in women, and enhanced inclusion of women in clinical research. Implementation of these recommendations is critical to closing the gap in cardiovascular outcomes between sexes.

Conclusion

Sex-specific differences in cardiovascular risk are underpinned by distinct epidemiological, pathophysiological, and clinical features that influence disease burden, presentation, and response to therapy. Recognition and integration of these differences into clinical practice are essential for optimizing cardiovascular prevention, diagnosis, and management. Ongoing research and guideline refinement will further enhance sex-tailored care, ultimately improving outcomes for both men and women.